Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Ryoichi Sawada"'
Autor:
Mariko Shimada, Masayuki Saruta, Haruna Miyashita, Kazuki Takakura, Yuki Maruyama, Yuko Iwashita, Yoshihiro Akita, Ryosuke Miyazaki, Naoki Shibuya, Ryoichi Sawada, Takahiko Toyonaga, Toshiyuki Sakurai
Publikováno v:
Digestive Diseases. 40:239-245
Objectives: The aim of this study was to propose an endoscopic classification system for ulcerative lesions on the ileocecal valve and investigate its relevance to the underlying etiology. Methods: Among the 60,325 patients who underwent colonoscopy
Autor:
Machi Suka, Haruna Miyashita, Yusuke Nagata, Shigeharu Hamatani, Masaaki Noguchi, Toshiyuki Sakurai, Masayuki Saruta, Yuki Maruyama, Ryoichi Sawada, Ryosuke Miyazaki, Yoshitaka Ando, Y Akita, Tomohiro Kato, Kazuki Sumiyama, T Yamasaki
Publikováno v:
Digestion. 102:921-928
Background and Aims: In gastrointestinal neuroendocrine tumors (GI-NETs), tumor size and grading based on cellular proliferative ability indicate biological malignancy but not necessarily clinically efficient prognostic stratification. We analyzed tu
Autor:
Y Akita, T Yamasaki, Kazuki Sumiyama, Masaaki Noguchi, Tomohiro Kato, Ryoichi Sawada, Toshiyuki Sakurai, Masayuki Saruta, Haruna Miyashita, Ryosuke Miyazaki, Yusuke Nagata, Yuki Maruyama, Akihisa Hidaka
Publikováno v:
In Vivo
Background/Aim: Malignant lymphoma (ML) cases with overlapping gastrointestinal (GI) lesions are often encountered. We aimed to elucidate the importance of examining the GI tract in patients with ML and assess the overlap rate. Patients and Methods:
Autor:
Emi Noguchi, Kan Yonemori, Rui Kitadai, Narikazu Boku, Kazuki Sudo, Atsuo Takashima, Ryoichi Sawada, Yusuke Nagata, Tatsunori Shimoi
Publikováno v:
BMC Cancer
BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
Background Standard treatment for malignant peritoneal mesothelioma has not been established, and systemic chemotherapy is administered according to malignant pleural mesothelioma. We previously reported the efficacy of cisplatin plus pemetrexed as f
Autor:
Narikazu Boku, Ryoichi Sawada, Yusuke Nagata, Natsuko Okita, Hiroshi Imazeki, Atsuo Takashima, Masahiko Aoki, Hidekazu Hirano, Satoru Iwasa, Masayuki Saruta, Masashi Ishikawa, Hirokazu Shoji, Ken Kato, Yoshitaka Honma
Publikováno v:
PLoS ONE
PLoS ONE, Vol 16, Iss 9, p e0257551 (2021)
PLoS ONE, Vol 16, Iss 9, p e0257551 (2021)
Background In clinical practice, the same chemotherapeutic agents are occasionally reused (re-challenge) after failure of all available standard chemotherapy options for metastatic colorectal cancer (mCRC). However, the benefits of re-challenge chemo
Autor:
Masaaki Noguchi, Masahisa Ohkuma, Masayuki Saruta, Utako Ishimoto, Saori Yatabe, Yasuhiro Takeda, Yusuke Nagata, Ken Eto, Eijiroh Nagasaki, Makoto Kosuge, Ryoichi Sawada, Katsushi Amano
Publikováno v:
Annals of Oncology. 32:S190
Autor:
Eijiroh Nagasaki, Takashi Nishimura, Katsushi Amano, Yusuke Nagata, Daisuke Ito, Masahisa Ohkuma, Makoto Kosuge, Masaaki Noguchi, Masayuki Saruta, Saori Yatabe, Yasuhiro Takeda, Ken Eto, Shigemasa Sasaki, Ryoichi Sawada, Hiroshi Sugano
Publikováno v:
Annals of Oncology. 31:S157-S158
Autor:
Yoshinori Arai, Masaaki Noguchi, Sadamu Homma, Yusuke Nagata, Katsushi Amano, Masayuki Saruta, Ryoichi Sawada, Takashi Nishimura
Publikováno v:
Annals of Oncology. 31:S108
Autor:
Tomohiro Kano, Hayato Mikuni, Masaaki Noguchi, K. Nakatsuka, Masashi Ishikawa, C. Kinoshita, Masayuki Saruta, Yusuke Nagata, Utako Ishimoto, Ryoichi Sawada, K. Harada, Katsushi Amano, Takashi Nishimura
Publikováno v:
Annals of Oncology. 30:ix64
Background The combination of gemcitabine and nab-paclitaxel (GnP) has been established as the first-line chemotherapy in patients (pts) with metastatic pancreatic cancer (M-PC). However, the efficacy of the therapy in pts with borderline resectable
Autor:
Utako Ishimoto, Ken Eto, Eijiro Nagasaki, Ryoichi Sawada, Tomohiro Kano, Hayato Mikuni, Masayuki Saruta, Masahisa Ohkuma, Takashi Nishimura, Katsuhiko Yanaga, Masaaki Noguchi, Kentaro Harada, Katsushi Amano, Yusuke Nagata, Masashi Ishikawa
Publikováno v:
Annals of Oncology. 30:vi118
Background Fluoropyrimidine (Fp) is one of the key drugs of chemotherapy in unresectable colorectal cancer (CRC), and usually used not only in first-line but also in second-line as beyond progression. The efficacy in combination of irinotecan, oxalip